United Therapeutics Corporation (UTHR) Completes Phase 3 Enrollment for Promising PAH Drug Ralinepag

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. United Therapeutics Corporation stands eighth among the most undervalued stocks.

United Therapeutics Corporation (NASDAQ:UTHR) is among the most undervalued stocks to invest in. It is a biotechnology company focused on treating pulmonary arterial hypertension (PAH) and advancing organ transplantation alternatives through xenotransplantation and regenerative medicine.

On June 23, 2025, United Therapeutics Corporation (NASDAQ:UTHR) announced the completion of enrollment in its Phase 3 ADVANCE OUTCOMES trial for ralinepag, a once-daily oral prostacyclin receptor agonist for PAH. The trial enrolled 728 patients, and top-line data is expected in the first half of 2026. Ralinepag showed strong Phase 2 results, significantly reducing pulmonary vascular resistance, a key marker of disease progression.

The successful enrollment marks a major milestone as ralinepag could become a new standard of care, offering a more convenient and potentially more effective oral therapy for PAH. This move strengthens the company’s leadership in PAH, complementing its existing Tyvaso franchise and advancing its pipeline of differentiated therapies aimed at improving patient outcomes.

United Therapeutics Corporation (NASDAQ:UTHR) is also presenting long-term ralinepag data at leading scientific conferences, reinforcing its commitment to transparency and scientific rigor. While exploring related areas such as idiopathic pulmonary fibrosis (IPF) and organ transplant innovations, the company’s near-term focus remains firmly on transforming PAH treatment through innovative, patient-friendly therapies.

While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.